XLAB Research is recognized as one of the strongest computer science research teams outside the academic world in Slovenia. XLAB Research employs 36 people, where 4 have a PhD in Computer Science, 7 have Master's degrees and 9 are post-graduate students. Altogether the whole company’s team consists of 61 experts in the field of computer science, electronics and mathematics, with an access to additional expert resources (around 10 to 20 experts).
Expertise: we have experience in GIS data analysis, visualization and integration; natural disaster simulations, especially hydrographical; emergency response support and training; high-volume information processing, integration and analysis. The company also has experts in the fields of distributed systems, where we focus on Cloud computing (connectors to Cloud platforms, SLA, PaaS implementations) and their security, reliability and dependability.
As one of the world's largest professional services providers we offer our customers and partners over 30 years experience in the field of strategy, concept, product, brand and service & policy development. We distinguish between five stages: thorough reframing, original concepting, desirable styling, hardcore engineering and appropriate retailing. With over 120 professionals we manage the entire process from engineering to prototyping and offer you unrivalled production support.
Founded more than 70 years since its origin Zeltia group has been involved in the biopharmaceutical and chemical. Zeltia publicly traded since 1963 and in the continuous market since 1998.
The holding is a world-leading biopharmaceutical company specialised in the development of marinebased drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer
care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer’s disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.